The European Commission approved the use of monoclonal antibody Emgality (galcanezumab) for injection one time per month for migraine prevention in adults who suffered from migraines attacks at least four times per month as PharmaTimes reported.
One month ago the FDA also approved the use of the drug in this indication in the same patient population.
Emgality developed specifically for migraine prevention blocks calcitonin gene-related peptide (CGRP) receptor associated with migraine attacks and also reduces the rate of migraine attacks per month.
According to three clinical studies (EVOLVE-1, EVOLVE-2, and REGAIN) where 2 901 subjects participated, the group received Emgality experienced a significant decrease in MHD compared to the placebo group.
In EVOLVE-1 and EVOLVE-2, more than 1/3 of subjects achieved MHD decrease by at least 75% compared to 19.3% and 17.8%, respectively, in the placebo group.
Migraine occupies the third place in the world in the list of the most common diseases and takes the leading position among neurological diseases causing disability.